ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1118

The Association of Hand OA with Paid an Unpaid Work Impairment and Related Costs: The Hand Osteoarthritis in Secondary Care Cohort
Abstract Number: 0871

The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Abstract Number: 1059

The Association of Pain and Sleep in Relation to Depressive Symptoms Among Older Adults with Arthritis
Abstract Number: 1036

The Association of Patient Uncertainty with Mental Health in Systemic Autoimmune Rheumatic Diseases
Abstract Number: 0954

The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis
Abstract Number: 0910

The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Abstract Number: 1315

The Best Cardiovascular Risk Algorithm to Predict the Presence of Carotid Plaque in Psoriatic Arthritis Patients
Abstract Number: 0557

The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
Abstract Number: 1269

The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Abstract Number: 0594

The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study
Abstract Number: 1931

The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis
Abstract Number: 0346

The CB-CAPillaryTM Test Kit: A Tool for Point-of-Care Assays to Measure Cell-Bound Complement Activation Products
Abstract Number: 0960

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Abstract Number: 0298

The Clinical Phenotype of Isolated Ocular and Oral Dryness in Sjogren Syndrome, Fulfilling the 2016 ACR-EULAR Classification Criteria
Abstract Number: 0407

The Clinical Role of T1 Mapping Cardiac Magnetic Resonance Imaging for Detecting Cardiac Involvement in the Early Stage of Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].